These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Accurate determination of energy needs in hospitalized patients. Boullata J; Williams J; Cottrell F; Hudson L; Compher C J Am Diet Assoc; 2007 Mar; 107(3):393-401. PubMed ID: 17324656 [TBL] [Abstract][Full Text] [Related]
30. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome. López-Lerma I; Estrach MT J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537 [TBL] [Abstract][Full Text] [Related]
31. Resting energy expenditure and body composition in patients with newly detected cancer. Cao DX; Wu GH; Zhang B; Quan YJ; Wei J; Jin H; Jiang Y; Yang ZA Clin Nutr; 2010 Feb; 29(1):72-7. PubMed ID: 19647909 [TBL] [Abstract][Full Text] [Related]
32. Prospective study of resting energy expenditure changes in head and neck cancer patients treated with chemoradiotherapy measured by indirect calorimetry. García-Peris P; Lozano MA; Velasco C; de La Cuerda C; Iriondo T; Bretón I; Camblor M; Navarro C Nutrition; 2005; 21(11-12):1107-12. PubMed ID: 16308133 [TBL] [Abstract][Full Text] [Related]
33. Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Shiraki M; Terakura Y; Iwasa J; Shimizu M; Miwa Y; Murakami N; Nagaki M; Moriwaki H Nutrition; 2010 Mar; 26(3):269-75. PubMed ID: 19695831 [TBL] [Abstract][Full Text] [Related]
34. Resting energy expenditure in lung and colon cancer. Nixon DW; Kutner M; Heymsfield S; Foltz AT; Carty C; Seitz S; Casper K; Evans WK; Jeejeebhoy KN; Daly JM Metabolism; 1988 Nov; 37(11):1059-64. PubMed ID: 3185289 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer. Scott HR; McMillan DC; Watson WS; Milroy R; McArdle CS Lung Cancer; 2001 Jun; 32(3):307-12. PubMed ID: 11390012 [TBL] [Abstract][Full Text] [Related]
36. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a. Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303 [TBL] [Abstract][Full Text] [Related]
37. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Dentener MA; Creutzberg EC; Schols AM; Mantovani A; van't Veer C; Buurman WA; Wouters EF Thorax; 2001 Sep; 56(9):721-6. PubMed ID: 11514694 [TBL] [Abstract][Full Text] [Related]